VialPT-141 10 mg vial
Also known as Bremelanotide
Sexual wellness
Investigated for central melanocortin and arousal pathways.
- Ships from Canada in 1–2 business days
- Free shipping over $120
Place your order, then send the e-Transfer. We pack it as soon as it arrives.
For research use only. Not for human consumption.
Complete your setup
Needles and wipes are free. Water is $19.
- Bacteriostatic Water
$19.00 · To reconstitute the powder
- Needles
Free · For reconstitution
- Alcohol Wipes
Free · To prep the vial stopper
Compare. Side by side, from the research.
About PT-141
PT-141 is studied for its role in the signaling pathways tied to desire and motivation. Research focuses on central melanocortin receptors rather than the vascular system.
How it works
- Central Signaling
- Studied for activity at melanocortin receptors within the central nervous system, associated with motivation and arousal circuits.
- Non-Vascular Pathway
- Research explores a mechanism upstream of vascular response, working through neural signaling rather than circulation.
What you need
- Bacteriostatic Water
- Needles
- Alcohol Wipes
- A protocol guide comes with every order
Shipping & payment
- Packed and dispatched within 1–2 business days
- Delivered across Canada in 2–5 business days, tracked
- Temperature-controlled packaging where the product needs it
- Free shipping on orders over $120
- Prices in CAD · pay by Interac e-Transfer
- Format
- Lyophilised powder in a sealed vial
- Strength
- 10 mg per vial
- Storage
- Refrigerate, away from light. Once reconstituted, keep refrigerated and use within the window on the insert.
- Reconstitution
- 2 mL bacteriostatic water for this 10 mg vial (5 mg/mL)
- Route in research
- Subcutaneous
- SKU
- P41
Handling
- 1ReconstituteAdd bacteriostatic water down the side of the vial. Swirl, never shake. Agitation damages the peptide chain.
- 2StoreRefrigerate at 2–8°C once mixed. Reconstituted peptide is stable for the window given in your protocol guide.
- 3Measure with the calculator Use an insulin syringe at the units your protocol specifies. Rotate sites and log what you take.
- Purity
- High-performance liquid chromatography (HPLC), by an independent laboratory
- Identity
- Mass spectrometry, on the same batch
- How often
- Every batch
- COA
- The certificate of analysis is matched to the lot code printed on your vial
- Evidence
- Approved analog
Check your lot
Every vial carries a lot code. Enter it, or scan the QR on the label, to see its expiry and certificate of analysis.
Approved analogBremelanotide, the name under which PT-141 is also known, has received regulatory approval for hypoactive sexual desire disorder, and its safety profile has been reported across a clinical development program that included phase 3 trials.
What research examines
- Hypoactive sexual desire disorder in women
- Central melanocortin receptor signaling
- Desire and motivation pathways
- Neural mechanisms upstream of vascular response
Reported in studies
- Safety profile evaluated across a clinical development program that included phase 3 randomized controlled trials
- Specific adverse events are not summarized on this page; the published phase 3 safety analysis is the primary reference
- Safety data for research contexts outside the approved indication are limited
Published research protocols
1 mg, as needed, 30 minutes before activity
Research protocols have used 500–2,000 mcg per administration, as needed.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Measure with the calculatorCoreX AI
Ask about PT-141
Plain answers, from the basics to the studies.
Research information, not medical advice.
Often researched with PT-141
Vial
Vial
FAQ
Questions, answered
PT-141, also known as Bremelanotide, is a peptide studied for its role in signaling pathways tied to desire and motivation. Research focuses on central melanocortin receptors rather than on the vascular system. Bremelanotide has been the subject of multiple reviews and a clinical development program, and published literature describes its regulatory approval for hypoactive sexual desire disorder. CoreX supplies PT-141 for laboratory research use only.
Research describes PT-141 as an agonist at melanocortin receptors in the central nervous system. These receptors are associated with motivation and arousal circuits. Rather than acting directly on circulation, the peptide is studied for influence on neural signaling that sits upstream of vascular response. This central, non-vascular mechanism is the main feature distinguishing it in the research literature on sexual-health pathways.
The most extensively studied area is hypoactive sexual desire disorder in women, which is the subject of several reviews and a phase 3 clinical program. Published reviews cover its physiology, assessment context, and clinical development history, including its first regulatory approval in 2019. Earlier work, including a 2004 review under the PT-141 name, examined its development as an investigational compound acting through central melanocortin signaling.
The safety profile of Bremelanotide has been analyzed across its clinical development program, including phase 3 randomized controlled trials, and that analysis is the primary published reference for adverse events. Specific adverse event rates are not summarized here. Safety data outside the approved clinical indication, including in research settings with different protocols, are limited, and findings from the clinical program should not be assumed to apply to every context.
Research protocols have used 500 to 2,000 mcg per administration, on an as-needed basis, via the subcutaneous route. These figures describe amounts reported in research settings and are not a recommendation for any individual. Each CoreX order ships with a protocol guide for laboratory reference. Researchers should consult the primary literature for the specific study designs in which these amounts were used.
You may also like
Pen
Vial
Vial
Vial

